Table 1.

Summary of the deposition fractions* measured during all in vitro trials and those predicted by the CFD simulations in this study for transnasal aerosol delivery to the preterm infant nose-throat model at a target peak flow rate of 3 L/min

Location of deposition	Single-RE		Dual-RE
	In vitro	CFD**	In vitro	CFD**
Device (%)	23.8 (2.3)	N/A	28.0 (1.5)	N/A
Patient Interface (%)	14.4 (0.9)	17.9	14.3 (4.4)	13.9
Nose & Throat (%)	32.9 (7.2)	29.7	24.9 (2.2)	20.3
Tracheal Filter (%)	28.9 (1.5)	28.5	32.9 (2.8)	37.7

*Values are mean (SD) formulation mass expressed as a percentage (n=3) of the device loaded dose

**CFD predictions were adjusted by the experimental emitted fraction to represent a percentage of the loaded dose